PNC Financial Services Group Inc. lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report ...

The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

Each Baqsimi device includes 1 dose of glucagon and cannot be refused ... the dose does not need to be inhaled. If there is no response after 15 minutes, an additional 3mg dose from a new device ...

Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...

AlphaQuest LLC reduced its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 35.9% in the ...

With more patients taking GLP-1s [glucagon-like peptide 1] and losing ... Do they come off biologics? Do they use inhaled corticosteroids less frequently? Olayiwola and Alexis reported no relevant ...

Gvoke, Xeris’s ready-to-use glucagon therapy ... The company’s key candidate, seralutinib, is inhaled and targets pathways involved in abnormal cellular growth problems, inflammation, and ...

Amphastar is a biopharmaceutical company focusing primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products.

Kore.ai, a global leader in enterprise AI, today announced the Kore.ai Agent Platform, an enterprise-grade multi-agent orchestration infrastructure for developing, deploying, and managing ...

By inhibiting DPP4, vildagliptin causes an increase in glucagon like peptide-1 (GLP-1 ... With the exception of inhaled insulin, none of the other recently approved diabetes medications are ...